ArticleClinical rheumatology2025
Molecular analysis of TNFAIP3, PTPN22, IRF5, and IL-10 gene polymorphisms in palindromic rheumatism.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association between body mass index and palindromic rheumatism risk and outcomes: a case-control study.Clinical rheumatology · 2026Article
- Comparing clinical outcomes of rheumatoid arthritis by onset type: palindromic rheumatism, undifferentiated arthritis, and typical rheumatoid arthritis.Clinical rheumatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivePalindromic rheumatism (PR) is characterized by frequent and irregular attacks of pain and swelling in the joints and peri-articular structures. In this study, we investigated TNFAIP3, PTPN22, IRF5, and IL-10 genes' single-nucleotide polymorphisms (SNPs) in patients with PR.
methodsIn a cross-sectional study, patients with a diagnosis of PR and two control groups, including rheumatoid arthritis (RA) patients and healthy controls (HCs), were recruited. All participants were Azeri. The TNFAIP3 (rs2230926, rs5029937), PTPN22 (rs1217407, rs1217413), IRF5 (rs10954213, rs2004640), and IL-10 (rs1800872, rs1800896) gene SNPs were genotyped.
resultsEight SNPs were genotyped in 25 PR patients, 41 RA patients, and 40 HCs. The TT genotype of TNFAIP3 rs2230926 and GG genotype of IL10 rs1800872 polymorphisms were less common in the PR group compared to the RA and HC groups. The C allele of TNFAIP3 rs2230926 polymorphism was more common in the PR group compared to the RA and HC groups. The TC genotype and C allele of IL10 rs1800896 and AG genotype of IRF5 rs10954213 polymorphisms were more common in the PR group compared to the HCs; however, there were no significant differences between the PR and RA groups. No significant difference was observed in the distribution of TNFAIP3 rs5025937, IRF5 rs2004640, PTPN22 rs1217413, and PTPN22 rs1217407 genotypes and alleles between the studied groups.
conclusionsCarrying C allele of TNFAIP3 rs2230926, CC and TC genotypes and C allele of IL10 rs1800896, and AG genotype of IRF5 rs10954213 polymorphisms are associated with PR in the Azeri population. Key Points • The TT genotype of the TNFAIP3 rs2230926 polymorphism is less common in patients with palindromic rheumatism than in patients with rheumatoid arthritis and healthy individuals. • The GG genotype of the IL10 rs1800872 polymorphism is less common in patients with palindromic rheumatism than in patients with rheumatoid arthritis and healthy individuals. • The CC and TC genotypes, C allele of IL10 rs1800896, and AG genotype of IRF5 rs10954213 polymorphism are more common in patients with palindromic rheumatism than in healthy individuals, but there is no difference between patients with palindromic rheumatism and rheumatoid arthritis.
Indexed as
Identifiers
41023437What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.